Lord J M, White S I, Bailey C J, Atkins T W, Fletcher R F, Taylor K G
Br Med J (Clin Res Ed). 1983 Mar 12;286(6368):830-1. doi: 10.1136/bmj.286.6368.830.
To investigate the effect of metformin on insulin receptor binding and diabetic control, eight obese type II diabetic patients were studied before treatment, after one and four weeks of taking metformin (500 mg thrice daily), and four weeks after withdrawal of the drug. After one and four weeks of treatment the number of erythrocyte insulin receptors had increased by 116% and 184% respectively. This was due almost entirely to an increase in the number of low affinity binding sites. The number of receptors was still raised four weeks after metformin had been withdrawn. Diabetic control as assessed by urinary glucose, glycosylated haemoglobin (HbA1), and glucose tolerance values was significantly improved during metformin treatment, while plasma insulin concentrations were not altered. These results indicate that metformin produces a rapid and protracted increase in low affinity insulin receptors in type II diabetes, associated with greater insulin sensitivity and improved diabetic control.
为研究二甲双胍对胰岛素受体结合及糖尿病控制的影响,对8名肥胖的II型糖尿病患者在治疗前、服用二甲双胍(每日3次,每次500毫克)1周和4周后以及停药4周后进行了研究。治疗1周和4周后,红细胞胰岛素受体数量分别增加了116%和184%。这几乎完全是由于低亲和力结合位点数量增加所致。停用二甲双胍4周后,受体数量仍有所增加。在二甲双胍治疗期间,通过尿糖、糖化血红蛋白(HbA1)和葡萄糖耐量值评估的糖尿病控制情况得到显著改善,而血浆胰岛素浓度未发生改变。这些结果表明,二甲双胍可使II型糖尿病患者低亲和力胰岛素受体迅速且持久地增加,同时伴有更高的胰岛素敏感性和更好的糖尿病控制。